Compare HP Inc (HPQ) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Incyte Corporation — how do they compare? HP Inc trades at $30.2 (market cap $29.25B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays a 3.7% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Incyte Corporation for 33 Days on average.
| HPQ | INCY | |
|---|---|---|
Market Cap | $29.25B | $22.85B |
Volume | 10,025,806 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $35.48 | $129.93 |
52-Week Low | $18.20 | $83.80 |
Typical Hold Time | 69 Days | 33 Days |
Enterprise Value | $35.42B | $18.35B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.44, up 0.62% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid cash flow generation of $460M in 2025. Valuation appears attractive with P/E of 12.38 and P/S of 0.51, though the company faces headwinds from projected PC market declines in 2027.
HPQ offers value characteristics with reasonable valuation metrics and consistent dividend payments, but faces significant business risks from PC market contraction. Analyst sentiment is mixed with 30.8% buy ratings versus 53.8% holds, reflecting uncertainty about growth prospects amid industry challenges.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
